BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16785122)

  • 1. Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
    Tueger S; Chen FE; Ahsan G; McDonald V; Andrews VE; Madrigal JA; Kazmi MA
    Haematologica; 2006 Jun; 91(6 Suppl):ECR16. PubMed ID: 16785122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma.
    Malaspina F; Pellegrini C; Casadei B; Argnani L; Zinzani PL
    Acta Haematol; 2017; 137(4):191-194. PubMed ID: 28427046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
    Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S
    Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the management of diffuse large B-cell lymphoma.
    Habermann TM
    Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).
    Todeschini G; Tecchio C; Pasini F; Benedetti F; Cantini M; Crippa C; Draisci M; Pizzolo G
    Cancer; 2005 Aug; 104(3):555-60. PubMed ID: 15959910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thalidomide therapy in relapsed diffuse large B-cell lymphoma in elderly patients. Three cases].
    Wohner N; Varga G; Szloboda P; Farkas P; Masszi A; Horváth L; Szombath G; Várkonyi J; Benedek S; Masszi T
    Orv Hetil; 2017 Oct; 158(41):1642-1648. PubMed ID: 29025286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
    Masaki Y; Sawaki T; Shimoyama K; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Ogawa N; Wano Y; Sugai S; Hirose Y; Umehara H
    Rinsho Ketsueki; 2005 Sep; 46(9):1074-7. PubMed ID: 16440768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era.
    Mounier N; Gisselbrecht C
    Curr Opin Oncol; 2011 Mar; 23(2):209-13. PubMed ID: 21169834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
    Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
    Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.
    Shin HJ; Yoon DH; Lee HS; Oh SY; Yang DH; Kang HJ; Chong SY; Park Y; Do Y; Lim SN; Jo JC; Lee WS; Chung JS;
    Exp Hematol; 2016 Jan; 44(1):3-13. PubMed ID: 26325332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.